Research Reports

Key takeaways

Revenue reached $700.5K as operations commenced, reflecting initial commercialization of biologics and procedures per management commentary.

Gross profit of $191.7K yielded 27.4% margin, demonstrating pricing discipline as CODM monitors gross profit per Item 7.

Operating loss totaled -$366.5K or -52.3% margin, as expenses exceeded gross profit, potentially requiring third-party capital.

Net loss of -$395.5K reflects ongoing scaling costs outpacing revenue growth, consistent with liquidity discussion.

Operating cash outflow of -$179.2K drove -$192.4K free cash flow after $13.2K capex, highlighting working capital demands.

Full analysis

Despite topline progress, operating income fell to -$366.5K, a -52.3% margin, as operating expenses overwhelmed gross profit. Management notes that inability to cover expenses with gross profit may necessitate third-party capital, underscoring early-stage scaling pressures in clinic network buildout and R&D. Net income reached -$395.5K, mirroring liquidity challenges detailed in Item 7, where the net loss directly impacts capital resources.

Cash flow dynamics reveal operational cash use of -$179.2K, exacerbated by $13.2K capital expenditures to yield -$192.4K free cash flow. This burn stems from working capital needs in a growth phase, with short-term financial instruments carrying values approximating fair values due to their nature. Management relies on its line-of-credit facility—supported by related parties—for bridge capital, receivables financing, and operating needs, anticipating continued revenue growth.

ADIA · Adia Nutrition, Inc.

Summary

Key takeaways

Full analysis